(Q44636715)

English

A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate

scientific article published on 18 April 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

author name string

Mark C Genovese

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Eric Lee

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Julie Satterwhite

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Melissa Veenhuizen

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Damon Disch

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Pierre-Yves Berclaz

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Stephen Myers

7

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Gregory Sides

8

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Olivier Benichou

9

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

language of work or name

0 references

publication date

18 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

72

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1453-1460

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Guidelines for the management of rheumatoid arthritis: 2002 Update

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202864

21 January 2018

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202864

21 January 2018

Cracking the BAFF code.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202864

21 January 2018

Alterations on peripheral blood B-cell subpopulations in very early arthritis patients.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202864

21 January 2018

Roles of B cells in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202864

21 January 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202864

21 January 2018

Bayesian clinical trials

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202864

21 January 2018

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202864

21 January 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202864

21 January 2018

Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202864

21 January 2018

Rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202864

21 January 2018

Identifiers

10.1136/ANNRHEUMDIS-2012-202864

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44636715&oldid=2113625398"